Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial.

@article{Hiraoka1994RecombinantHN,
  title={Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial.},
  author={Akira Hiraoka and Toru Masaoka and Hideyuki Mizoguchi and Shigetaka Asano and Yoshihisa Kodera and Keiichi Kitamura and Fumimaro Takaku and Sadao Komemushi},
  journal={Japanese journal of clinical oncology},
  year={1994},
  volume={24 4},
  pages={205-11}
}
In a randomized double-blind placebo-controlled phase III clinical trial, the effects of a non-glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (CSF 39-300) were investigated in patients who had received allogeneic bone marrow transplantation. CSF 39-300 was administered at a daily dose of 10 micrograms/kg (maximum dose, 300 micrograms/body) via three-hour intravenous infusions from days 1 to 21 following reinfusion of the marrow. Twenty-eight patients received… CONTINUE READING